Amir Avan

1.3k total citations
23 papers, 968 citations indexed

About

Amir Avan is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Amir Avan has authored 23 papers receiving a total of 968 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Molecular Biology and 5 papers in Cancer Research. Recurrent topics in Amir Avan's work include Pancreatic and Hepatic Oncology Research (13 papers), Colorectal Cancer Treatments and Studies (5 papers) and Liver physiology and pathology (4 papers). Amir Avan is often cited by papers focused on Pancreatic and Hepatic Oncology Research (13 papers), Colorectal Cancer Treatments and Studies (5 papers) and Liver physiology and pathology (4 papers). Amir Avan collaborates with scholars based in Netherlands, Italy and Iran. Amir Avan's co-authors include Elisa Giovannetti, Godefridus J. Peters, Niccola Funel, Abolfazl Avan, Mina Maftouh, Tjeerd J. Postma, Guido Cavaletti, C Ceresa, Ugo Boggi and Leticia G. León and has published in prestigious journals such as PLoS ONE, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Amir Avan

23 papers receiving 956 citations

Peers

Amir Avan

ONCOL

MB

CR

PRM

PFM

Sujatha Jagadeeswaran United States

Ariel Ka-Man Chow Hong Kong

Enzo Mammano Italy

Klaas M. Govaert Netherlands

Nobuya Yamada Japan

Aparna Jayachandran Australia

Sorin Armeanu–Ebinger Germany

Martin Zweifel Switzerland

Massimo Pancione Italy

Anna Fioravanti Italy

Sujatha Jagadeeswaran United States

Amir Avan

360 ×0.7

ONCOL

465 ×0.9

MB

197 ×0.8

CR

169 ×1.3

PRM

76 ×0.9

PFM

Citations per year, relative to Amir Avan Amir Avan (= 1×) peers Sujatha Jagadeeswaran

Countries citing papers authored by Amir Avan

Since Specialization

Citations

This map shows the geographic impact of Amir Avan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amir Avan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amir Avan more than expected).

Fields of papers citing papers by Amir Avan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amir Avan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amir Avan. The network helps show where Amir Avan may publish in the future.

Co-authorship network of co-authors of Amir Avan

This figure shows the co-authorship network connecting the top 25 collaborators of Amir Avan. A scholar is included among the top collaborators of Amir Avan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amir Avan. Amir Avan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Cascioferro, Stella, Camilla Pecoraro, Amir Avan, et al.. (2021). SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance. Cancer Drug Resistance. 4(4). 904–922. 2 indexed citations

2.

Firuzi, Omidreza, Pei Pei, Btissame El Hassouni, et al.. (2019). Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. Cancers. 11(5). 638–638. 60 indexed citations

3.

Massihnia, Daniela, Amir Avan, Niccola Funel, et al.. (2017). Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. Journal of Hematology & Oncology. 10(1). 9–9. 69 indexed citations

4.

Rovithi, Maria, Amir Avan, Niccola Funel, et al.. (2017). Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. Scientific Reports. 7(1). 44686–44686. 71 indexed citations

5.

Shahidsales, Soodabeh, et al.. (2017). Association of a Genetic Variant in ABCB1 Gene with the Tumor Size in Patients with Breast Cancer. 1(Supplementary 1). 0–0. 1 indexed citations

6.

Avan, Abolfazl, Tjeerd J. Postma, C Ceresa, et al.. (2015). Platinum-Induced Neurotoxicity and Preventive Strategies: Past, Present, and Future. The Oncologist. 20(4). 411–432. 184 indexed citations

7.

Maftouh, Mina, Amir Avan, Niccola Funel, et al.. (2014). miR-211 Modulates Gemcitabine Activity Through Downregulation of Ribonucleotide Reductase and Inhibits the Invasive Behavior of Pancreatic Cancer Cells. Nucleosides Nucleotides & Nucleic Acids. 33(4-6). 384–393. 54 indexed citations

8.

Avan, Abolfazl, Amir Avan, Tessa Y. S. Le Large, et al.. (2014). AKT1 and SELP Polymorphisms Predict the Risk of Developing Cachexia in Pancreatic Cancer Patients. PLoS ONE. 9(9). e108057–e108057. 36 indexed citations

9.

Nedaeinia, Reza, Amir Avan, Mostafa Manian, Rasoul Salehi, & Majid Ghayour‐Mobarhan. (2014). EGFR as a Potential Target for the Treatment of Pancreatic Cancer: Dilemma and Controversies. Current Drug Targets. 15(14). 1293–1301. 49 indexed citations

10.

Maftouh, Mina, Amir Avan, Niccola Funel, et al.. (2014). A Polymorphism in the promoter is Associated with EZH2 Expression but not with Outcome in Advanced Pancreatic Cancer Patients. Pharmacogenomics. 15(5). 609–618. 6 indexed citations

11.

Peters, Godefridus J., Abolfazl Avan, Mariëlle Gallegos Ruiz, et al.. (2014). Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer.. PubMed. 34(1). 435–42. 21 indexed citations

12.

Maftouh, Mina, Amir Avan, Elena Galvani, Godefridus J. Peters, & Elisa Giovannetti. (2013). Molecular Mechanisms Underlying the Role of MicroRNAs in Resistance to Epidermal Growth Factor Receptor-Targeted Agents and Novel Therapeutic Strategies for Treatment of Non-Small-Cell Lung Cancer. Critical Reviews™ in Oncogenesis. 18(4). 317–326. 10 indexed citations

13.

Avan, Amir, Viola Caretti, Niccola Funel, et al.. (2013). Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma. Cancer Research. 73(22). 6745–6756. 69 indexed citations

14.

Giovannetti, Elisa, Qiuyan Wang, Amir Avan, et al.. (2013). Role of CYB5A in Pancreatic Cancer Prognosis and Autophagy Modulation. JNCI Journal of the National Cancer Institute. 106(1). djt346–djt346. 50 indexed citations

15.

Avan, Amir, Paola Pacetti, Michele Reni, et al.. (2013). Prognostic factors in gemcitabine–cisplatin polychemotherapy regimens in pancreatic cancer: XPD‐Lys751Gln polymorphism strikes back. International Journal of Cancer. 133(4). 1016–1022. 23 indexed citations

16.

Avan, Amir, Francesco Crea, Elisa Paolicchi, et al.. (2012). Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells. Molecular Cancer Therapeutics. 11(8). 1735–1746. 80 indexed citations

17.

Giovannetti, Elisa, Arjan van der Velde, Niccola Funel, et al.. (2012). High-Throughput MicroRNA (miRNAs) Arrays Unravel the Prognostic Role of MiR-211 in Pancreatic Cancer. PLoS ONE. 7(11). e49145–e49145. 57 indexed citations

18.

Avan, Amir, Karl Quint, Francesco Nicolini, et al.. (2012). Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer. Current Pharmaceutical Design. 19(5). 940–950. 2 indexed citations

19.

Avan, Amir, Karl Quint, Niccola Funel, et al.. (2012). Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer. Current Pharmaceutical Design. 19(5). 940–950. 52 indexed citations

20.

Avan, Amir, Karl Quint, Francesco Nicolini, et al.. (2012). Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer. Current Pharmaceutical Design. 19(5). 940–950. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact